Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

 

AstraZeneca acquired Omthera Pharmaceuticals on July 18, 2013, to strengthen AstraZeneca's late-stage cardiovascular disease pipeline. As an AstraZeneca company, Omthera remains dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.